Alexza Pharmaceuticals - Welcome
Revolutionary Technology

Revolutionary Technology

The Staccato system enables rapid onset of action for many drugs.

Simple and Intuitive

Simple and Intuitive

The Staccato system is breath actuated, and a patient simply inhales to administer the drug dose.

Fast-Acting, Non-Invasive Treatment

Fast-Acting, Non-Invasive Treatment

Unlike injections, the Staccato system is noninvasive and does not require caregiver assistance.

Improved Patient Therapy

Improved Patient Therapy

Products for the treatment of acute and intermittent conditions.

Products with Unique Therapeutic Effect

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.

See Staccato® in action

Product Pipeline

We have already demonstrated that more than 200 FDA-approved compounds are feasible for delivery by the Staccato® system. Currently we have six development programs focused on five acute and intermittent conditions.

More about our Products

Recent News

  • June 15, 2009
    Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

  • June 11, 2009
    Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

  • May 11, 2009
    Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

Noteworthy

2008annual.jpg

2008 Annual Report
Accelerating Relief. 
Expanding Markets.

PDF with 10-K (800k)

Download the annual report
View other reports & filings

Building a Commercial Infrastructure

As our development pipeline grows and our clinical candidates advance in the development process, we have begun building a commercial infrastructure to support what we hope will be a growing portfolio of approved pharmaceutical products.

More on Our Growing Business